Premium
Mutations of carnitine palmitoyltransferase II (CPT II) in Japanese patients with CPT II deficiency
Author(s) -
Yasuno T,
Kaneoka H,
Tokuyasu T,
Aoki J,
Yoshida S,
Takayanagi M,
Ohtake A,
Kanazawa M,
Ogawa A,
Tojo K,
Saito T
Publication year - 2008
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1111/j.1399-0004.2008.00986.x
Subject(s) - compound heterozygosity , cytosine , valine , genotype , mutation , carnitine , gene , carnitine o palmitoyltransferase , endocrinology , biology , medicine , microbiology and biotechnology , genetics , enzyme , biochemistry , amino acid , beta oxidation
Carnitine palmitoyltransferase II (CPT II) deficiency is an inherited disorder involving β‐oxidation of long‐chain fatty acids. CPT II deficiency is a wide‐spectrum disorder that includes a lethal neonatal form, an infantile form, and an adult‐onset form. However, the ethnic characteristics and the relationship between genotype and clinical manifestation are not well understood. We investigated three non‐consanguineous Japanese patients with CPT II deficiency and examined cell lines from 4 unrelated patients and 50 healthy donors. The CPT 2 gene was typed by direct DNA sequencing of polymerase chain reaction‐amplified gene products. Case 1 (infantile form) was heterozygous for a phenylalanine to tyrosine substitution at position 383 (p.F383Y) and a novel valine to leucine substitution at 605 (p.V605L). Cases 2, 4, and 5 (infantile form) and case 3 (adult‐onset form) were heterozygous for a single mutation at F383Y. Case 6 (adult‐onset form) was compound heterozygous at the CPT 2 locus, with deletion of cytosine and thymine at residue 408, resulting in a stop signal at 420 (p.Y408fsX420), and an arginine to cysteine substitution at position 631 (p.R631C). Case 7 (adult‐onset form) was homozygous for the p.F383Y mutation. In conclusion, we identified p.F383Y mutations in six of seven patients with CPT II deficiency and two novel variants of the coding gene: p.Y408fsX420 and p.V605L. These mutations differ from those in Caucasian patients, who commonly harbor p.S113L, p.P50H, and p.Q413fsX449 mutations; therefore, our data and those of other Japanese groups suggest that the p.F383Y mutation is significant in Japanese patients with CPT II deficiency.